Carvolix: 100% of Kalios' 15 Patients Achieve 3-Year Goal
Carvolix announced on Monday that all patients treated with its adjustable mitral ring Kalios have achieved the primary goal at 3 years, without any adverse device-related events. A positive clinical outcome, but limited to 15 patients: a promising validation overshadowed by questions of statistical power ahead of the planned FDA submission in 2027.
100% Clinical Success, but Only on 15 Patients
Carvolix (ISIN: FR0013333077) reports that all 15 patients who reached the 3-year follow-up show mitral insufficiency of grade ≤ 2+, meeting the primary efficacy criterion of the Optimise II study. Zero adverse device-related events have been reported up to 3 years. The coaptation length of the mitral leaflets improved from 3.9 mm at baseline to 6.4 mm at 3 years, confirming a sustained structural improvement in valvular function. However, this clinical perfection should be viewed in context: of the 20 patients initially treated and followed up at 1 year, only 15 reached the 3-year mark. The Optimise II study is still at the pivotal stage: it plans to enroll up to 100 patients to have 62 evaluable at 1 year. The current sample size remains very limited for a study supporting a future regulatory approval request.
Kalios, the Only Percutaneously Adjustable Ring
Kalios stands out as the only percutaneously adjustable mitral annuloplasty ring after initial implantation, allowing correction on a beating heart. Among the 20 patients in the Optimise II study, 6 underwent perioperative or subsequent adjustments without the need for extracorporeal circulation; a benefit that, according to Carvolix, could avoid reintervention cardiac surgery in 30 to 40% of patients within 5 years of implantation. Sebastien Ladet, CEO, emphasizes that this on-the-fly adjustment capability 'represents a new paradigm for mitral repair' and facilitates the sizing of the ring for all cardiac surgeons. The primary efficacy data have been submitted for peer review, and a related summary is proposed for scientific communication.
A $1.5 Billion Market, Targeting Commercialization in 2027
Carvolix estimates the mitral valve repair market at $1.5 billion in the US–Europe region, with an annual growth of 3.5%. The company plans to submit Kalios to the FDA for potential commercialization in 2027. The Optimise II study anticipates a 5-year post-surgery patient follow-up, the deployment and analysis of which will determine the regulatory and commercial trajectory of the device beyond this early validation.
